A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Buckingham Palace announces that King Charles III and Queen Camilla will meet Pope Leo XIV in Vatican City as part of a state visit to Italy in October. MSP Foysol Choudhury is suspended from Scottish Labour over an allegation of inappropriate conduct. 29 September – Chancellor Rachel Reeves makes her keynote speech to the Labour Party Conference. 30 September – Starmer makes his keynote speech to the 2025 Labour Party Conference. Ed Davey reshuffles his Liberal Democrat frontbench.
== Etymology == The word "cirrhosis" is a neologism derived from Greek: κίρρωσις; kirrhos κιρρός, meaning "yellowish, tawny" (the orange yellow colour of the diseased liver) and the suffix -osis, i.e., "condition" in medical terminology. While the clinical entity was known before, René Laennec gave it this name in an 1819 paper.
== History == Avobenzone was patented in 1973 and was approved in the EU in 1978. It was approved by the FDA in 1988. As of 2021, the FDA announced that they do not support avobenzone as being generally recognized as safe and effective (GRASE) citing the need for additional safety data. Avobenzone was banned in 2020 by the Palau government citing reef-toxicity concerns.
Sources: en.wikipedia.org
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new antihistamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation" and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better-stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg in surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterward. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders.
== Further reading == C. Siefridt, Cadmium contamination in the EU : A growing challenge, European Parliament Research Service, 2026. Hartwig, Andrea (2013). "Cadmium and Cancer". In Astrid Sigel; Helmut Sigel; Roland K. O. Sigel (eds.). Cadmium: From Toxicity to Essentiality. Metal Ions in Life Sciences. Vol. 11. Springer. pp. 491–507. doi:10.1007/978-94-007-5179-8_15. ISBN 978-94-007-5178-1. PMID 23430782. Agency for Toxic Substances and Disease Registry (ATSDR) (2012). Toxicological Profile for Cadmium. U.S. Department of Health and Human Services, Public Health Service. https://www.atsdr.cdc.gov/toxprofiles/tp5.pdf Nordberg, Gunnar F. (2007). Handbook on the toxicology of metals (3rd ed.). Academic Press. pp. 445–486. ISBN 978-0-12-369413-3.
Men from the 110th Naval Construction Battalion arrived on Eniwetok between 21 and 27 February 1944 and began clearing the island for construction of a bomber airfield. A 2,100-meter (6,900 ft) by 120-meter (390 ft) runway with taxiways and supporting facilities was built. The first plane landed on 11 March. By 5 April the first operational bombing mission was conducted. The base was later named for Lieutenant John H. Stickell. In mid-September 1944 operations at Wrigley Airfield on Engebi Island were transferred to Eniwetok. US Navy and Marine units based at Eniwetok included:
=== Neuromorphic computer chips === Neuromorphic engineering is a branch of neuroscience that deals with creating functional physical models of neurons for the purposes of useful computation. The emergent computational properties of neuromorphic computers are fundamentally different from conventional computers in the sense that they are complex systems, and that the computational components are interrelated with no central processor.One example of such a computer is the SpiNNaker supercomputer. Sensors can also be made smart with neuromorphic technology. An example of this is the Event Camera's BrainScaleS (brain-inspired Multiscale Computation in Neuromorphic Hybrid Systems), a hybrid analog neuromorphic supercomputer located at Heidelberg University in Germany. It was developed as part of the Human Brain Project's neuromorphic computing platform and is the complement to the SpiNNaker supercomputer, which is based on digital technology. The architecture used in BrainScaleS mimics biological neurons and their connections on a physical level; additionally, since the components are made of silicon, these model neurons operate on average 864 times (24 hours of real time is 100 seconds in the machine simulation) that of their biological counterparts. Recent advances in neuromorphic microchip technology have led a group of scientists to create an artificial neuron that can replace real neurons in diseases.
Sources: en.wikipedia.org
The pore sizes of technical membranes are specified differently depending on the manufacturer. One common distinction is by nominal pore size. It describes the maximum pore size distribution and gives only vague information about the retention capacity of a membrane. The exclusion limit or "cut-off" of the membrane is usually specified in the form of NMWC (nominal molecular weight cut-off, or MWCO, molecular weight cut off, with units in Dalton). It is defined as the minimum molecular weight of a globular molecule that is retained to 90% by the membrane. The cut-off, depending on the method, can by converted to so-called D90, which is then expressed in a metric unit. In practice the MWCO of the membrane should be at least 20% lower than the molecular weight of the molecule that is to be separated. Using track etched mica membranes Beck and Schultz demonstrated that hindered diffusion of molecules in pores can be described by the Rankin equation. Filter membranes are divided into four classes according to pore size:
== Playwrights == Peter Barnes, playwright Steven Berkoff, playwright, actor, author, and theatre director Ashley Blaker, comedian and television producer; writer for TV and radio and longtime collaborator with Matt Lucas: was producer of Little Britain and Rock Profile. Lucas described Blaker as "the UK's only Orthodox comedian". Blaker's Off-Broadway show, Strictly Unorthodox, opened in 2017 at The Theater Center. and his second Off-Broadway show, Goy Friendly opened in February 2020, at SoHo Playhouse. Ben Elton (born 3 May 1959) comedian, actor, author, playwright, lyricist and director; was a part of London's alternative comedy movement of the 1980s and writer on the sitcoms The Young Ones and Blackadder, as well as stand-up comedian on stage and television; style in the 1980s was left-wing political satire; Elton is cousin of singer Olivia Newton-John; Elton's father is from a German-Jewish family and Elton's mother, who was raised in the Church of England, is of English background; has published 17 novels and written numerous rock operas and musicals. Ronald Harwood (né Horwitz; 9 November 1934 – 8 September 2020) was a South African Jewish -born British author, playwright, and screenwriter, best known for his plays for the British stage as well as the screenplays for The Dresser (for which he was nominated for an Oscar) and The Pianist, for which he won the 2003 Academy Award for Best Adapted Screenplay. He was nominated for the Best Adapted Screenplay Oscar for The Diving Bell and the Butterfly (2007); cousin of Antony Sher.
Johnson, British journalist and historian, contracted the disease in March after injuring his foot while swimming. His leg was amputated above the knee. 2011: Jeff Hanneman, guitarist for the thrash metal band Slayer, contracted the disease. He died of liver failure two years later, on May 2, 2013, and it was speculated that his infection was the cause of death. However, on May 9, 2013, the official cause of death was announced as alcohol-related cirrhosis. Hanneman and his family had apparently been unaware of the extent of the condition until shortly before his death. 2011: Peter Watts, Canadian science fiction author, contracted the disease. On his blog, Watts reported, "I'm told I was a few hours away from being dead ... If there was ever a disease fit for a science-fiction writer, flesh-eating disease has got to be it. This ... spread across my leg as fast as a Star Trek space disease in time-lapse." 2013: British actress Georgie Henley revealed in 2022 that she had contracted the disease several weeks after starting at Cambridge University and that it had almost claimed her life. 2014: Daniel Gildenlöw, Swedish singer and songwriter for the band Pain of Salvation, spent several months in a hospital after being diagnosed with necrotizing fasciitis on his back in early 2014. After recovering, he wrote the album In the Passing Light of Day, a concept album about his experience during the hospitalization. 2014: Ricky Bartlett, SAG-AFTRA actor and S.O.V.A.S. voiceover artist, lost both legs to NF. He contracted the disease during a trip to Wyoming and South Dakota.
Platyhelminthes: Diphyllobothrium sp. Nanophyetus sp. Taenia saginata Taenia solium Fasciola hepatica See also: Tapeworm and Flatworm Nematode: Anisakis sp. Ascaris lumbricoides Eustrongylides sp. Toxocara Trichinella spiralis Trichuris trichiura Protozoa: Acanthamoeba and other free-living amoebae Cryptosporidiosis Cyclospora cayetanensis Entamoeba histolytica Giardia lamblia Sarcocystis hominis Sarcocystis suihominis Toxoplasma
Another emerging and promising application of freeze casting is the production of porous foams for green hydrogen generation through advanced thermochemical processes like Chemical Loop Combustion (CLC) and the Steam Iron Process (SIP). These processes leverage the unique properties of porous metal structures, such as optimized reaction kinetics, enhanced thermal efficiency, and sustainability. In Chemical Loop Combustion (CLC), foams made from materials like iron oxides act as oxygen carriers, enabling fuel combustion without direct air contact, separating CO2 for capture while producing high-purity hydrogen. Similarly, in Steam Iron Process (SIP), dendritic pore structures ensure efficient water vapor distribution and maximize hydrogen yield. The precise control over porosity and thermal properties afforded by freeze casting, along with the use of eco-friendly solvents like camphene, positions these foams as a vital innovation for scalable and sustainable hydrogen production, contributing to the fight against climate change.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.